San Antonio, TX, United States, 12th Dec 2025 – At the San Antonio River Authority’s sold-out Holly Jolly Kayaking event, four GlowRow team members secured public tickets like everyone else and slipped quietly into the water. No fanfare. No announcement. No stage set for impact, just four clear kayaks joining a community paddle beneath the holiday lights.

But the Riverwalk has a way of noticing things that aren’t trying to be noticed.

As the GlowRow vessels glided under the bridges, with glowpaddles piercing the water like lightsabers… something shifted. The chatter along the walkways softened. People paused mid-stride, mid-sip, mid-sentence, as though the water itself had asked them to look. One phone lifted, then five, then a crowd, until the entire stretch of river seemed to glow not just from the kayaks, but from the attention drawn toward them.

What began as a quiet moment of participation became a shared moment of wonder, the kind that reminds you how rare it is to surprise a city that’s seen everything.

“We weren’t trying to make a statement. We just wanted to be part of the event. Yet somehow the moment grew bigger than us… the phones, the smiles, the people leaning over the rails. It was a reminder that light travels farther than you think, especially when you don’t intend to shine it,” said Zack Jurasek, Founder of GlowRow. 

“This wasn’t our show,” Zack added. “We were just one small part of a community paddle, but for a few minutes, the Riverwalk lit up in a way none of us expected.”

“For our team, paddling the Riverwalk during the holidays was already special… the reaction from the community made it unforgettable.”

GlowRow has guided more than 45,000 nighttime paddlers across Texas using proprietary lighting systems engineered in-house to withstand nightly operations, saltwater environments, vibration, and long-duration runtime. The company has received multiple awards from the Texas State Tourism office, international recognition from the UK Travel & Hospitality Awards, and USA Today’s #2 Best Kayak Tour in the U.S. for 2025.

Wednesday night was never planned as a showcase, yet something about the illuminated kayaks against the Riverwalk’s holiday backdrop created a moment that resonated with everyone who saw it.

GlowRow extends its appreciation to the San Antonio River Authority for hosting the Holly Jolly event and maintaining one of Texas’s most iconic waterways. Any future conversations about expanded opportunities in San Antonio will be approached with deep respect for the Riverwalk, its culture, and its community.

For more details visit 

Email: info@glowrow.com

Call: 702-720-GLOW

Media Contact

Organization: GlowRow® Team

Contact Person: Media Relations

Website: https://glowrow.com/

Email: Send Email

Contact Number: +17027204569

City: San Antonio

State: TX

Country:United States

Release id:38934

The post GlowRow’s Unplanned Spotlight at San Antonio’s Holly Jolly Kayaking Event Captures Public Attention appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

United States, 12th Dec 2025 — A1 Appliance Repair, one of the region’s fastest-growing home service companies, proudly announces the expansion of its professional Appliance Repair in Charlotte, NC services. The company continues to set a new standard of reliability, transparency, and customer care for homeowners throughout the Charlotte metropolitan area.

A Trusted Leader in Appliance Repair

Founded with a mission to make appliance repair more accessible, honest, and efficient, A1 Appliance Repair has built a strong reputation for delivering high-quality solutions backed by certified technicians and years of hands-on experience. The company provides comprehensive diagnostics, maintenance, and repair for all major appliance types, including:

  • Refrigerators and freezers
  • Washers and dryers
  • Dishwashers
  • Ovens, stoves, and cooktops
  • Microwaves
  • Garbage disposals
  • Water heaters
  • Additional household appliances

Every technician undergoes ongoing training to stay current with the latest technologies, brands, and repair standards—ensuring accuracy, safety, and long-lasting results for every service call.

Reliable and Fast Appliance Repair in Charlotte, NC

A1 Appliance Repair places a strong emphasis on convenience and fast turnaround times. Residents in Charlotte and surrounding areas can schedule appointments by phone or online, with flexible availability and rapid response to urgent repair needs.

To enhance the customer experience, the company has implemented:

  • Extended service hours and broader scheduling windows
  • Advanced diagnostic tools for faster, more accurate assessments
  • Transparent, upfront pricing with no hidden fees
  • Warranties on parts and labor
  • Priority service options for time-sensitive repairs

A1 Appliance Repair’s goal is to minimize downtime and help customers restore essential household appliances quickly and affordably.

Commitment to Customer Satisfaction

Customer satisfaction remains a cornerstone of the company’s values. A1 Appliance Repair has developed a service approach focused on honesty, communication, and respect for every home. Clients frequently highlight the team’s professionalism, prompt arrival, and clear explanations of repair options.

To maintain and improve service quality, the company has established an internal quality-control system that includes:

  • Multi-step inspection of completed work
  • Follow-up communication to confirm customer satisfaction
  • Improved logistics for faster technician dispatch
  • Continuous performance monitoring

These efforts ensure that every interaction meets the company’s high standards.

Growing Local Presence & Community Involvement

As a proud local business, A1 Appliance Repair is committed not only to growth, but also to giving back to the Charlotte community. The company has supported local families in need by offering discounted essential repairs and plans to expand its community assistance programs in the coming year.

In addition, A1 Appliance Repair is investing in operational improvements, including increasing inventory of OEM parts, adding new technicians to accommodate service demand, and enhancing digital tools for scheduling and customer communication.

About A1 Appliance Repair

A1 Appliance Repair is a full-service appliance repair company serving Charlotte, NC and surrounding areas. Specializing in diagnostics, maintenance, and repair of major household appliances, the company is known for its reliable service, upfront pricing, and superior customer experience. A1 Appliance Repair is dedicated to helping homeowners restore comfort and functionality to their homes quickly and professionally.

For more information, visit the official website:
 https://a1appliance-home-services.com/

Media Contact

Organization: A1 Appliance Repair, LLC

Contact Person: Ihor Storozhuk

Website: https://a1appliance-home-services.com/

Email: Send Email

Contact Number: +17043075004

Address:426 Church St N, Concord, CA – 28025, United States

Country:United States

Release id:38931

The post A1 Appliance Repair Expands High-Quality Appliance Repair Services Across Charlotte, NC appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

United Kingdom, 12th Dec 2025 – Recently, the cryptocurrency market has faced renewed volatility. With major liquidity engines collapsing and up to $5 billion flowing out of ETFs, Bitcoin (BTC) prices are under pressure, and market uncertainty is on the rise.

ETF funds are generally seen as an important indicator of institutional investor confidence. Their outflow often signals tightening market liquidity and higher price volatility.

Analyst Ted Piro pointed out that, given the current market environment, investors should approach such fund outflows with caution. He asked:
Will BTC experience another major drop?

If institutions reduce their holdings, the increase in Bitcoin supply could put downward pressure on prices. Historical data shows that large-scale fund movements often precede price adjustments, further increasing market uncertainty.

As a result, retail investors have begun to adjust their strategies. Instead of relying solely on short-term market opportunities, they are focusing on early accumulation, wealth building, and creating sustainable cash flow. In discussions about BTC investment strategies, Investor Hash’s automated digital asset platform is frequently mentioned, allowing users to participate in managed investment plans and earn daily returns without technical setup or manual trading.

Why is Investor Hash So Popular?

Investor Hash is known for its:

  • Green energy-powered data centers, ensuring sustainable operation.
  • Transparent and automated asset management, enabling predictable returns.
  • Regulated infrastructure: No hardware, maintenance, or technical expertise is required; users simply allocate funds into digital asset plans to earn stable returns.

The platform is registered in the UK and regulated by authorities. It uses international-grade security systems, including McAfee® and Cloudflare®, to protect user funds and data to a bank-level standard. All earnings are processed via smart contracts in real-time, ensuring transparency and traceability. Investor Hash currently serves users in over 180 countries and regions and is trusted by over 2 million investors worldwide.

How Does Investor Hash Ensure Fund Security?

Investor Hash prioritizes fund safety with a multi-layered, comprehensive protection system:

  • Cold Wallet Custody: Over 80% of client funds are stored offline, minimizing risk.
  • Asset Insurance: All digital assets are covered by international insurance, providing global protection.
  • AI Smart Risk Control: AI monitors transactions in real-time to prevent fraud, money laundering, and abnormal fund movements.
  • External Audits and Monitoring: PwC conducts regular security and compliance audits to ensure transparency.
  • Global Security Network: Enterprise-grade Cloudflare firewall and McAfee cloud security provide round-the-clock protection.

This systematic security architecture allows Investor Hash to offer a compliant, auditable, and uninterrupted investment environment.

How to Participate in Investor Hash and Earn Daily Returns

Investors can participate in three simple steps:

  1. Register an Account – Sign up with your email and receive a $15 registration bonus.
  2. Select an Investment Plan – Invest as little as $100 to start participating in automated digital asset plans.
  3. Start Asset Management – After allocating funds, returns are credited daily, and principal is automatically returned when the plan expires.

Investment Plan Examples (for illustration only, not guaranteed returns):

Plan Type Investment Amount Term Total at Maturity (Principal + Estimated Returns)
Starter Plan $100 2 days $106
Basic Plan $1,000 12 days $1,156
Classic Plan $5,000 25 days $6,875
Advanced Plan $12,000 35 days $19,140
Advanced Plan (Large) $30,000 40 days $51,600
Super Plan $120,000 49 days $261,120

Click here to learn more about Investor Hash investment plans

Conclusion

While the $5 billion ETF outflow and liquidity engine collapse have put short-term pressure on Bitcoin prices, whether BTC will experience another major drop depends on multiple factors: institutional behavior, macroeconomic trends, and market sentiment.

For retail investors, understanding market risk and adopting a prudent strategy is critical. Leveraging regulated platforms like Investor Hash to participate in automated digital asset plans can help achieve stable, predictable returns in a volatile market.

Visit Investor Hash today to explore investment plans and earn daily returns.

 

Media Contact

Organization: Investor Hash

Contact Person: Lola Farmer

Website: https://investorhash.com/

Email: Send Email

Country:United Kingdom

Release id:38886

Disclaimer: The information provided above is for general informational purposes only and does not constitute financial, investment, or trading advice. Cryptocurrency markets are highly volatile, and readers should conduct their own independent research and consult with a qualified professional before making any financial decisions.

The post Crypto Liquidity Engine Collapses: Will BTC Drop Again After $5 Billion ETF Outflow appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

SHENZHEN, CHINAChina Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.

 

With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.

 

Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.

 

The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.

 

More Information about Y-3 for Injection

The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.

 

The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.

 

On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.

 

About Stroke

According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

 

Reference

  1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.
  2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Worcester, Massachusetts, 11 Dec 2025, ZEX PR WIRE, As debates over privacy, free speech, and policing continue to unfold nationwide, local residents like Kevin Wall of Worcester are encouraging more community awareness around civil liberties and individual rights.

Wall, who has lived in Worcester for over a decade, says many people care about these issues but don’t always know where to start. “Most people I talk to want things to be fair and transparent,” Kevin Wall said. “They’re concerned about surveillance, about how schools handle discipline, about what kind of data companies and the government collect. But they don’t always feel equipped to speak up.”

Though not affiliated with any organization, Wall often shares resources from civil rights groups like the ACLU, especially those related to Massachusetts policies and digital rights. He follows court decisions and legislative changes and encourages others to do the same. “You don’t have to be an expert. Just being informed helps you spot when something isn’t right.”

In Massachusetts, recent civil liberties conversations have included facial recognition technology bans, school-based surveillance tools, bail reform, and expanded voting access. Organizations like the ACLU of Massachusetts have weighed in on many of these issues, publishing legal analysis and policy recommendations.

Worcester itself has seen growing interest in these topics. In recent years, the city has hosted forums on data privacy, transparency in school policies, and police oversight. Wall sees this as a sign of a more engaged public. “It’s not about being political,” he said. “It’s about understanding how systems work and making sure people are treated fairly.”

He says the rise of AI and digital tracking tools has made the public role more important than ever. “The tools are changing fast. You need people who are paying attention and asking questions.”

Wall is particularly focused on issues that affect everyday life: student discipline policies, use of technology in public spaces, and due process protections in local courts. “You can’t protect your rights if you don’t know what they are,” he said. “Groups like the ACLU do a good job breaking it down.”

For Worcester residents looking to get more involved, Wall recommends starting small. “Read a case summary. Sign up for an email list. Go to a local meeting. Even asking questions at a school board or city council meeting makes a difference.”

While he doesn’t speak publicly or run a group, Wall believes that quiet civic engagement still matters. “There are lots of ways to contribute without being front and center.”

He hopes more residents in Worcester will take interest in how rights are shaped and protected at the local level. “We all benefit when more people pay attention. Whether it’s about speech, privacy, education, or equal treatment, these issues affect all of us.”

Worcester, Massachusetts, 11 Dec 2025, ZEX PR WIRE, From school board meetings to courtroom challenges, the conversation around civil liberties in America is evolving. In cities like Worcester, residents such as Kevin Wall are quietly helping keep those conversations alive.

Wall isn’t a politician or spokesperson. He’s a longtime Worcester resident who takes an active interest in civil rights and regularly shares articles and legal updates with friends and neighbors. He says staying informed is part of being a responsible member of the community. “It’s not about having all the answers,” he said. “It’s about knowing enough to ask the right questions.”

Across the country, major civil liberties issues are in the spotlight—digital surveillance, student speech, reproductive rights, and access to public records among them. The ACLU and other legal groups continue to play a key role in shaping public understanding and defending constitutional protections.

Wall keeps tabs on this work, particularly from the ACLU of Massachusetts. “They’re one of the groups that actually explains things in plain language,” he said. “I follow their email briefings and court updates.”

In Worcester, topics like facial recognition, police transparency, and equity in school discipline have generated local interest. Wall believes these conversations are healthier when more people feel empowered to participate. “When you understand your rights, you’re more likely to speak up,” he said. “And when regular people speak up, public systems tend to work better.”

Although Wall doesn’t attend public events or speak on panels, his role is more grassroots. He brings up civil liberties topics in everyday conversation and encourages others to learn more. “People are surprised by how much these things touch their lives—how a policy might affect their kid at school or the way local police handle data.”

He’s especially concerned about how fast technology is changing the landscape. “AI tools, data collection, automated decisions—these are things that need public oversight,” Wall said. “You don’t need to be paranoid, but you should know what’s happening.”

Wall represents a growing number of residents who take an interest in public life without making it their job. “Not everyone wants to go to rallies or run for office,” he said. “But that doesn’t mean they don’t care. Being informed is a kind of participation.”

The ACLU continues to advocate for strong protections around voting access, LGBTQ+ rights, free expression, and immigration policy—many of which have direct implications for Worcester residents. Wall believes that raising awareness is a shared responsibility. “Organizations can only do so much. People need to take that extra step—read more, talk more, think more critically.”

As legal and political battles continue across the country, local voices like Kevin Wall’s reflect a broader truth: civil liberties aren’t just an issue for lawyers and lawmakers. They belong to everyone. And in Worcester, more residents are starting to take notice.

Ventura, California, 11 Dec 2025, ZEX PR WIRE, Dr. Matthew Longwill Ventura uses a structured form of energy medicine to help clients identify and correct the energetic blocks that often sit behind chronic symptoms. Through Be Vital Energetics, he focuses on precise energetic scanning, simple explanations, and remote sessions that address imbalance across physical, emotional, mental, and energetic layers.

Energetic imbalance can influence headaches, joint pain, back tension, sleep issues, digestive distress, and recurring discomfort that does not resolve through standard care. Dr. Longwill’s work studies the pattern behind these symptoms. He looks at how energy flow becomes disrupted and how these disruptions weaken the body’s ability to regulate and heal.

His background supports this method. Dr. Matthew Longwill holds a B.S. in Biology from Santa Clara University and a Doctor of Chiropractic from Life Chiropractic College West, magna cum laude. His training includes Nutrition Response Testing, Neuro Emotional Technique, Matrix Repatterning, Biomagnetism, and Bio Kinetics. These techniques share a focus on the body’s energetic communication network. This shared foundation shaped the development of Be Vital Energetics.

Energetic scanning follows a clear process. Dr. Longwill observes how energy moves through the field. He identifies where it slows, scatters, or becomes blocked. These patterns help explain why physical symptoms recur even when structural or biochemical findings appear normal. Once the pattern is clear, he applies targeted energetic work through remote sessions designed to restore flow and reduce interference.

Education is central to the practice. Clients learn simple testing methods they can use at home. These steps help people track their own patterns and support regulation between sessions. Dr. Matthew Longwill Ventura emphasizes clarity and direct language, so clients understand what is happening in their system and why.

Be Vital Energetics works with clients who have persistent symptoms that do not respond to conventional treatments. Many use energy medicine as a complement to their medical providers. The goal is not to replace medical care. The goal is to support the body’s natural ability to return to balance when energetic interference is cleared.

Dr. Longwill offers remote sessions only. Clients across different locations use this option for flexibility and consistent support. Many report improvements in clarity, comfort, and overall regulation after restoring flow in the energy field.

For more information, visit www.bevitalenergetics.com.

London, UK, 11 Dec 2025, ZEX PR WIRE, Stelios Tzellos, Ph.D., is a UK-based molecular biologist and pharmaceutical analyst whose work has contributed to the understanding of both viral gene regulation and oncology market dynamics. With academic roots in biochemistry and molecular biology, and an industry career spanning consulting and analytics roles, Dr. Tzellos has become known for his involvement in evidence-driven oncology strategy.

After earning his Bachelor’s and Master’s degrees in Biochemistry at Imperial College London, he completed a doctorate in Molecular Biology at the same institution. His Ph.D. research explored the differential regulatory effects of EBV EBNA-2 proteins on host and viral genes. The focus of this work was on understanding how a single amino acid substitution (S442D) in the EBNA-2 protein alters its ability to induce genes like CXCR7, contributing to the growth-promoting phenotype seen in Type 1 EBV.

Dr. Tzellos’ first-author publication, as well as co-authored papers from this research, are indexed in PubMed and remain relevant to those studying EBV biology, B-cell transformation, and transcriptional regulation.

Following completion of his Ph.D., Dr. Tzellos moved into pharmaceutical market analysis, beginning at GlobalData. There, as an Oncology and Haematology Analyst, he participated in market forecasting and treatment landscape evaluations. He was quoted in a 2014 industry report focused on the projected growth of the Hodgkin’s lymphoma treatment market. His comments highlighted the significance of Adcetris in reshaping access for premium-priced therapies targeting R/R disease subsets:

“Adcetris currently accounts for 77.6% of the total market and is predicted to make up 82.4% of sales by the end of the forecast period. Premium-priced pipeline therapies that target the R/R Hodgkin’s lymphoma population will find it easier to penetrate the market, as Adcetris has already opened the door for expensive therapeutics in this setting.”

That statement has since been cited in discussions about market entry barriers, payer dynamics, and the economics of targeted cancer therapies.

Dr. Tzellos later worked at IQVIA in a role that continued to focus on pharmaceutical analytics. His focus has remained within oncology and pharmaceutical strategy. He currently holds a role at AstraZeneca in the UK.

While not all of his industry work is in the public domain, his academic and consulting background has shaped a clear professional profile centered on evidence-based strategy and real-world data application. Dr. Tzellos’ public writing includes personal blog posts and medium articles covering the role of science in forecasting, the rise of real-world evidence in oncology, and transitions from academic research to commercial roles.

His interests extend beyond professional analytics. Dr. Tzellos is married with two children and is an active follower of sports such as football, basketball, and Formula 1. He enjoys music, regularly attends live performances, and takes on hands-on projects around the house. These personal interests provide balance to his data-heavy professional work and illustrate the range of his day-to-day experience.

By grounding strategic insights in scientific training and verified industry contributions, Stelios Tzellos represents a model of evidence-based thinking in pharmaceutical analytics.

London, UK, 11 Dec 2025, ZEX PR WIRE, Stelios Tzellos, Ph.D., continues to be recognized within the pharmaceutical industry for his contributions to oncology market analysis and strategic forecasting. With a formal background in molecular biology and biochemistry from Imperial College London and multiple years of applied experience in healthcare analytics, Tzellos’ work has informed commercial planning and strategic evaluation across multiple therapeutic areas, particularly within oncology.

Dr. Tzellos earned his Bachelor’s and Master’s degrees in Biochemistry and went on to complete a Ph.D. in Molecular Biology, all from Imperial College London. His doctoral research focused on Epstein-Barr virus (EBV) gene regulation, specifically the functional differences between EBNA-2 type 1 and type 2 proteins. His findings, published in peer-reviewed journals, helped expand understanding of how EBV regulates the expression of cellular genes like CXCR7 and viral genes such as LMP-1.

His academic contributions during his Ph.D. program include co-authorship of studies examining how specific amino acid changes in EBNA-2 affect the regulation of growth-promoting genes. One study, published in the Journal of General Virology in 2014, was titled “EBV EBNA-2 type 1 and type 2 proteins induce expression of the cellular CXCR7 and EBI2 genes through a mechanism involving a common motif in their transactivation domains.” Another article, where he was the first author, expanded on the same theme of differential gene activation.

In 2014, while working as an Oncology and Haematology Analyst for GlobalData, Dr. Tzellos was quoted in a widely circulated industry report forecasting trends in Hodgkin’s lymphoma treatment. That report examined the expanding use of Adcetris and the emergence of premium-priced therapies targeting relapsed or refractory (R/R) populations. In the report, Dr. Tzellos stated:

“Adcetris currently accounts for 77.6% of the total market and is predicted to make up 82.4% of sales by the end of the forecast period. Premium-priced pipeline therapies that target the R/R Hodgkin’s lymphoma population will find it easier to penetrate the market, as Adcetris has already opened the door for expensive therapeutics in this setting.”

The analysis helped contextualize the broader adoption of targeted agents and immunotherapies in hematologic malignancies and emphasized the commercial implications of label expansions and earlier-line use. Dr. Tzellos’ quote has since been referenced by healthcare publications analyzing pricing strategy and market evolution in oncology.

After his tenure at GlobalData, Dr. Tzellos joined IQVIA, where he continued to work in pharmaceutical analytics. He later moved into a commercial-facing analytics position at AstraZeneca in the UK. Across these roles, his focus has remained in strategic insight, analytics, and pharmaceutical development, particularly in oncology.

Dr. Tzellos’ professional experience intersects research, forecasting, and healthcare consulting. His work contributes to decision-making processes related to product planning, commercialization strategy, and global market evaluation. While he has not authored publicly available white papers under AstraZeneca or IQVIA, he continues to post periodically on Medium and LinkedIn about trends in pharmaceutical strategy and oncology analytics.

He resides in the United Kingdom with his wife and their two children. Outside of work, he has a range of personal interests including football, basketball, Formula 1, attending live music events, and engaging in DIY home projects.

Dr. Tzellos’ career exemplifies a transition from academic molecular biology research to high-impact pharmaceutical strategy and analytics. His ongoing work remains grounded in scientific evidence while addressing real-world commercial challenges in oncology drug development.

United States, 11th Dec 2025 — San Diego Asphalt Paving and Concrete (SDAPC), a leading name in asphalt and concrete construction solutions, proudly announces the continued expansion of its high-quality paving and pavement maintenance services throughout San Diego County. With more than 25 years of proven industry experience, the company has earned a strong reputation for delivering durable, reliable, and professionally engineered pavement solutions for commercial, municipal, and residential clients.

Founded in San Diego, SDAPC has established itself as a trusted service provider by maintaining a strict commitment to quality workmanship and long-lasting results. The company’s comprehensive service portfolio includes new asphalt installation, asphalt resurfacing, precision grading, milling, chip sealing, sealcoating, crack filling, asphalt patching, concrete flatwork, and full-service pavement maintenance. In addition, SDAPC offers parking lot striping exclusively as part of complete paving projects to ensure proper adhesion, safety compliance, and long-term performance.

“We take pride in doing the job right the first time,” said Phil M., spokesperson for San Diego Asphalt Paving and Concrete. “Our philosophy is simple—use the highest-quality materials, follow industry best practices, and treat each project with the same attention to detail we would give our own property. That commitment to excellence is why clients continue to trust us with their paving needs.”

As demand grows for properly engineered, long-lasting pavement solutions, SDAPC continues to expand its presence and capabilities across San Diego. By utilizing state-of-the-art equipment and advanced paving techniques, the company consistently delivers results that meet strict durability and safety standards. Whether handling large-scale commercial parking lots, industrial pavement installations, municipal roadway improvements, or residential driveways, SDAPC tailors every project to the unique needs of the property.

With San Diego’s infrastructure rapidly evolving and many roadways and parking areas aging, high-quality pavement solutions are essential. SDAPC remains committed to supporting the region with dependable, cost-effective services designed to withstand heavy traffic, changing weather conditions, and long-term environmental impacts. Clients benefit not only from superior workmanship but also from detailed project planning, transparent communication, and a customer-first approach that ensures satisfaction from start to finish.

For over two decades, SDAPC has played a significant role in enhancing the region’s infrastructure, helping property owners extend pavement lifespan, improve safety, and increase the visual appeal of their surfaces. As the company continues to grow, it remains dedicated to maintaining the high standards that have positioned it as one of Southern California’s most trusted paving contractors.

For more information visit http://sandiegoasphaltpavingandconcrete.com .

About San Diego Asphalt Paving and Concrete

San Diego Asphalt Paving and Concrete is a full-service asphalt and concrete contractor based in San Diego, California. With more than 25 years of experience, the company specializes in commercial paving, residential driveway construction, asphalt resurfacing, sealcoating, crack repair, chip sealing, milling, and concrete flatwork. Known for its precision workmanship and high-quality materials, SDAPC delivers durable, cost-effective pavement solutions backed by exceptional customer service and a commitment to long-term value.

Media Contact

Organization: San Diego Asphalt Paving and Concrete

Contact Person: Phil M.

Website: http://sandiegoasphaltpavingandconcrete.com/

Email: Send Email

Country:United States

Release id:38916

The post San Diego Asphalt Paving and Concrete Expands Premium Asphalt & Concrete Services Across San Diego County appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file